Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

计划入组 23,670 人 · 首次发布于 2021 年 5 月 27 日

Study of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older

计划入组 21,046 人

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

计划入组 3,159 人 · 首次发布于 2021 年 2 月 21 日

recombinant protein

recombinant fusion protein

recombinant klotho protein

Protein Sciences Corporation

United States

VBI Vaccines Inc

Canada

GLAXOSMITHKLINE VACCINES SRL

Italy

CEPI Partners with Samsung Biologics to Strengthen Global Vaccine Manufacturing for Future Pandemics

Vaccine Adjuvants Market Projected to Reach USD 6.19 Billion by 2035, Driven by mRNA and Oncology Vaccine Innovation

Novavax Advances Global Vaccine Development with Protein-Based Platform and Matrix-M Technology